AI Article Synopsis
Article Abstract
Background: Polyneuropathy (pnp) is recognized as a clinical feature of Parkinson's disease (PD). Whether pnp is a result of the alpha-synucleinopathy or related to treatment is debated. Previous studies support underlying disturbances in the methionine cycle mediated by L-dopa.
Objective: Describe possible relationships between methionine cycle metabolism and the development of pnp in L-dopa treated PD. Furthermore, we aim to investigate possible genetic risk factors by genotyping specific SNPs in enzymes involved in the abovementioned pathways.
Methods: In a cross-sectional study design, L-dopa treated PD patients (n = 33) and controls (n = 16) were evaluated with biochemical and genetic analyses. Subjects were assessed clinically and with regards to signs of pnp using established clinical neuropathy rating scales.
Results: 16/33 patients fulfilled a study diagnosis of pnp compared to 0 age-matched controls. Levels of homocysteine (Hcy) were significantly higher in patients with pnp (n = 16) compared to controls. A significant correlation between neuropathy scores and Hcy was seen in the whole patient group (n = 33). A significant difference in the genotype distribution of the COMT A158G polymorphism was demonstrated, favoring the low activity genotype in patients with pnp compared to both controls and patients without pnp.
Conclusions: Pnp is a prevalent condition in L-dopa treated PD and an association may exist with elevated levels of Hcy, possibly reflecting an underlying impaired cellular methylation capacity. Furthermore, an association may exist between the low activity COMT genotype and pnp. These preliminary findings and the suggested pathophysiological mechanisms should be confirmed in future large-scale studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/JPD-171127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bromocriptine Versus Levodopa and other treatments in Parkinson's Disease: an updated Meta-analysis Involving more than 4000 patients across 12 randomized clinical trials.
Acta Neurol Belg
December 2024
Department of Epidemiology and Biostatistics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Objectives: The purpose of this meta-analysis was to conduct a comparative study by systematically examining and analyzing trials that studied the impacts of levodopa and bromocriptine, either separately or together, in treating Parkinson's disease (PD).
Methods: An extensive literature search was conducted across PubMed (Medline), Scopus, and Web of Science databases, using targeted keywords for studies published up to October 2024. The methodological quality of included RCTs was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool, and bias evaluation was performed using RevMan (version 5).
While deep brain stimulation (DBS) remains an effective therapy for Parkinson's disease (PD), sources of variance in patient outcomes are still not fully understood, underscoring a need for better prognostic criteria. Here we leveraged routinely collected T1-weighted (T1-w) magnetic resonance imaging (MRI) data to derive patient-specific measures of brain structure and evaluate their usefulness in predicting changes in PD medications in response to DBS. Preoperative T1-w MRI data from 231 patients with PD were used to extract regional measures of fractal dimension (FD), sensitive to the structural complexities of cortical and subcortical areas.
View Article and Find Full Text PDFDopaminergic Treatment and Episodic Memory in Parkinson's Disease: A Meta-analysis of the Literature.
Neuropsychol Rev
December 2024
Laboratory of Neuropsychology of Memory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179, Rome, Italy.
To date, few studies have focused on the benefits of dopaminergic treatment on episodic memory functions in patients affected by Parkinson's disease (PD). We conducted a meta-analysis to determine the effects of pharmacological therapy with dopamine in alleviating episodic memory deficits in Parkinson's patients. A secondary aim was to evaluate the role of dopamine in episodic memory circuits and thus in different memory systems.
View Article and Find Full Text PDFEvaluating gait and postural responses to subthalamic stimulation and levodopa: A prospective study using wearable technology.
Eur J Neurol
January 2025
UOC Clinica Neurologica Rete Metropolitana NEUROMET, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Background: The efficacy of subthalamic stimulation on axial signs of Parkinson's disease (PD) is debated in the literature. This study delves into the dynamic interplay of gait and posture, specifically probing their nuanced response to subthalamic stimulation and levodopa.
Methods: We used wearable sensor technology to examine alterations in the spatiotemporal parameters of gait and posture in individuals with PD before and 6 months after subthalamic deep brain stimulation (STN-DBS) surgery.
Freezing of gait shapes the postural control of individuals with Parkinson's disease: Effect of visual information and medication states.
Clin Biomech (Bristol)
December 2024
Graduate Program in Physical Therapy, Universidade Cidade de São Paulo (UNICID), São Paulo, Brazil; Motion Analysis Lab, Universidade Cidade de São Paulo (UNICID), São Paulo, Brazil. Electronic address:
Background: Several measures of the center of pressure have been used to describe magnitude and structure of the postural sway in individuals with Parkinson's disease (PD). This study aimed to examine whether both the magnitude and structure of the center of pressure trajectory can differentiate PD individuals with and without freezing of gait in both On- and Off-medication states and with eyes open and closed.
Methods: Twenty-four individuals with PD (14 without and 10 with freezing of gait) were tested.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!